BRIEF REPORT

Combined Effect of Nonalcoholic Fatty Liver Disease and Impaired Fasting Glucose on the Development of Type 2 Diabetes

A 4-year retrospective longitudinal study

OBJECTIVE —To evaluate whether there is a difference in the association between nonalcoholic fatty liver disease (NAFLD) and incident diabetes based on the presence of impaired fasting glucose.

RESEARCH DESIGN AND METHODS—A total of 7,849 individuals (5,409 men and 2,440 women) without diabetes, who underwent comprehensive health check-ups annually for 5 years, were categorized into four groups by the presence of impaired fasting glucose and NAFLD at baseline. The association between NAFLD and incident diabetes was evaluated separately in groups with normal and impaired fasting glucose.

RESULTS—For 4 years, the incidence of diabetes in the NAFLD group was 9.9% compared with 3.7% in the non-NAFLD group, with multivariable-adjusted hazard ratio of 1.33 (95% CI 1.07–1.66). However, this higher risk for diabetes only existed in the impaired fasting glucose group.

CONCLUSIONS—Our study suggests that NAFLD has an independent and additive effect on the development of diabetes under conditions of impaired insulin secretion.

Diabetes Care 34:727–729, 2011

Nonalcoholic fatty liver disease (NAFLD) is reported to have an effect on incident diabetes (1–3). NAFLD coexists in a substantial percentage of patients with impaired fasting glucose (IFG) (4). This study was designed to ascertain whether there is a difference in the association between NAFLD and incident diabetes according to the presence of IFG.

RESEARCH DESIGN AND METHODS—Initial data were obtained from 10,950 individuals who participated in comprehensive health check-ups annually for 5 years (between January 2005 and December 2009). Among these, 3,101 were excluded for alcohol intake >20 g/day, type 1 or type 2 diabetes, positive serologic markers for hepatitis B or C virus, liver cirrhosis, or missing data. All analyses were performed on 7,849 individuals (5,409 men and 2,440 women) who were aged ≥20 years (mean age, 44.5 years; Supplementary Table 1).

We categorized all participants into four groups according to the presence of IFG and NAFLD in the 2005 records. The hazard ratio (HR) of incident diabetes associated with NAFLD was estimated overall and separately in the normal fasting glucose (NFG) and IFG groups using Cox proportional hazards analysis. Also, we evaluated the combined effect of IFG and NAFLD on incident diabetes. Statistical analysis was performed using SPSS 17 software (SPSS, Chicago, IL).

Anthropometric and biochemical variables were measured as described previously (5). Lifestyle information was self-reported.

All subjects had an abdominal ultrasoundogram (Logic Q700 MR, GE, Milwaukee, WI), and fatty liver was diagnosed based on known standard criteria, including hepatoportal echo contrast, liver brightness, deep attenuation, and vascular blurring, using a 3.5 MHz probe (6). Several experienced radiologists performed the ultrasound examinations.

IFG was defined as fasting plasma glucose between 100 and 126 mg/dL (7). The development of diabetes was assessed from the annual records of all participants and defined as fasting plasma glucose ≥126 mg/dL or A1C ≥6.5% (7). Also, subjects who had a history of diabetes or currently used insulin or oral antidiabetic drugs based on the self-report questionnaire at each visit were considered to have developed diabetes.

RESULTS—During the mean follow-up of nearly 4 years (47.4 ± 5.0 months), 435 of the 7,849 participants (5.5%) progressed to diabetes. The incidence of diabetes was 9.9% in the NAFLD group and 3.7% in the non-NAFLD group. In a multivariate model adjusted for age, sex, BMI, triglyceride, HDL cholesterol, smoking status, physical activity, alcohol intake, and coexisting IFG, subjects with NAFLD had an HR of 1.33 (95% CI 1.07–1.66) for the development of diabetes compared with the non-NAFLD groups (Supplementary Table 2). However, the significance of this association between NAFLD and incident diabetes was different based on whether IFG was present.
Participants with NAFLD had a significantly higher HR for the development of diabetes only if IFG was present, reaching 1.39 (95% CI 1.02–1.68), whereas the HR was 1.39 (95% CI 0.88–2.23) in the NFG groups. After multivariable adjustment, those with IFG alone had an HR of 6.79 (95% CI 5.03–9.16) for the development of diabetes compared with NFG subjects without NAFLD, whereas those with NAFLD alone had an HR of 1.39 (95% CI 0.93–2.08). Among the subjects with IFG and NAFLD, we observed further increased risk of diabetes, with an HR of 8.95 (95% CI 6.49–12.35; Table 1 and Supplementary Fig. 1).

**CONCLUSIONS**—When we separately analyzed the association between NAFLD and incident diabetes based on the presence of IFG, an independent association was only shown in the subjects with IFG. Early in the natural history of type 2 diabetes, insulin resistance is well established, but glucose tolerance remains normal because of a compensatory increase in insulin secretion (8,9). Although animal studies showed that fat accumulation in the liver inhibited insulin signaling in hepatocytes, which decreased insulin activity to glycogen synthase and increased gluconeogenesis (10,11), the resulting elevation in insulin concentration can overcome hepatic insulin resistance and cause a nearly normal suppression of hepatic glucose products (9), which could explain our inability to show an independent association between NAFLD and incident diabetes in the individuals with NFG. However, the presence of IFG indicates that β-cells already have impairment of insulin secretion and are unable to maintain a compensatory increase in insulin secretion (12). Our results differed according to the presence of IFG, suggesting that NAFLD has an independent effect on the development of diabetes under conditions of impaired insulin secretion.

The comparison of NAFLD with IFG helps us understand the relative importance of NAFLD in the development of diabetes. Although subjects with NAFLD alone were more obese and insulin resistant than those with IFG alone (Supplementary Table 3), the risk for incident diabetes was much higher in subjects with IFG alone than in those with NAFLD alone. However, the high risk of diabetes among subjects with IFG exaggerated by the presence of NAFLD, even after adjustment for BMI and other risk factors, indicates that IFG and NAFLD have an additive effect on the development of diabetes.

Several limitations to this study should be considered. The lack of a 2-h postload glucose test is a limitation because it might have resulted in inclusion of subjects with undiagnosed diabetes at baseline. The presence of impaired glucose tolerance was not considered, and this might also have an effect on the study results. Ultrasonography was used to diagnose fatty liver. Despite being considerably accurate, ultrasonography cannot identify fatty infiltration of the liver below the threshold of 30% (13). NAFLD is closely associated with abdominal obesity (14). However, our analysis was not adjusted for waist circumference reflecting abdominal obesity. Finally, we did not consider the use of other drugs for dyslipidemia in our analysis, and that might have influenced glucose levels (15).

This study suggests that NAFLD is an independent risk factor for diabetes. This independent association is shown particularly in individuals with IFG, indicating that NAFLD has an independent and additive effect on the development of diabetes under conditions of impaired insulin secretion.

**Acknowledgments**—This work was partially supported by the Samsung Biomedical Research Institute Grant (SBRI C-A8-223-2).
No potential conflicts of interest relevant to this article were reported.

J.C.B. contributed to study design, statistical analysis, and interpretation of results and wrote the manuscript. E.J.R. contributed to interpretation of results and reviewed and edited the manuscript. W.Y.L. contributed to study design and interpretation of results and reviewed and edited the manuscript. S.E.P. contributed to acquisition of data and discussion. C.Y.P. and K.W.O. reviewed and edited the manuscript. S.W.P. and S.W.K. contributed to discussion.

Parts of this study were presented in abstract form at the 8th International Diabetes Federation-Western Pacific Region Congress, Busan, Korea, 17–20 October 2010. The authors thank Hyun Il Seo, Kangbuk Samsung Hospital, for help with preparing the manuscript.

References

1. Fraser A, Harris R, Sattar N, Ebrahim S, Davey Smith G, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women’s Heart and Health Study and meta-analysis. Diabetes Care 2009;32:741–750

2. Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of type 2 diabetes in Korean adults. Diabet Med 2008;25:476–481

3. Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J Gastroenterol Hepatol 2010;25:352–356

4. Jimba S, Nakagami T, Takahashi M, et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet Med 2005;22:1141–1145

5. Bae JC, Cho YK, Lee WY, et al. Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects. Am J Gastroenterol 2010;105:2389–2395

6. Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. Br Med J (Clin Res Ed) 1986;292:13–15

7. American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care 2010;33(Suppl. 1):S11–S61

8. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3–19

9. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787–835, ix

10. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of fatty liver. Endocr Rev 2008;29:939–960

11. Samuel VT, Liu ZX, Qu X, et al. Mechanism of hepatic insulin resistance in nonalcoholic fatty liver disease. J Biol Chem 2004;279:32343–32353

12. Abdul-Ghani MA, DeFronzo RA. Pathophysiology of prediabetes. Curr Diab Rep 2009;9:193–199

13. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44–52

14. Jakobsen MU, Berentzen T, Sørensen TI, Overvad K. Abdominal obesity and fatty liver. Epidemiol Rev 2007;29:77–87

15. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735–742